Companies › Broadenbio
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BB102 FGFR4 inhibitor | FGFR4 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| BB3008 | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06143007 | BB3008 | Phase 1 | Advanced Solid Tumor | Oncology | May 2025 |
| NCT06258408 | BB102 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.